43m
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trialZURICH, Switzerland, May 27, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results